China SXT Pharmaceuticals Inc (SXTC) Stock Analysis
Verdict: AVOID
Relentless dilutive share issuances and collapsing sales (-34.6% YoY) destroy shareholder value despite nominal cash balance reserves.
Investment score: 10/100
Analysis as of
Is China SXT Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The TradeMates model maintains a strict AVOID recommendation on China SXT Pharmaceuticals (SXTC) due to systemic shareholder dilution, crashing revenues (-34.6% YoY), and extreme operating losses (-625.9% margin).
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 8/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
China SXT Pharmaceuticals Inc opportunities and risks
What speaks for SXTC
- Nominal Cash Cushion vs. Market Cap
What speaks against SXTC
- Massive Toxic Warrant and Convertible Facility Overhang
Frequently asked questions about China SXT Pharmaceuticals Inc (SXTC)
Is SXTC stock a good investment?
The TradeMates model rates China SXT Pharmaceuticals Inc as AVOID with an investment score of 10/100. The TradeMates model maintains a strict AVOID recommendation on China SXT Pharmaceuticals (SXTC) due to systemic shareholder dilution, crashing revenues (-34.6% YoY), and extreme operating losses (-625.9% margin). This is algorithmic model output, not personal investment advice.
Is SXTC stock a buy?
The TradeMates model verdict for SXTC is AVOID with an investment score of 10/100. Treat this as a model signal to review, not a personal buy recommendation.